

34. The test kit according to claim 20, wherein the ratio between the receptor-binding capacity of ligand immobilized on the solid phase and the ligand-binding capacity of the analyte-specific receptor substance is no more than about 1:20.

35. The test kit according to claim 23, wherein the ratio between the amount of ligand-binding analyte-specific receptor and the total amount of analyte-specific receptor is in the range of from about 1:5 to 1:100.

36. The test kit according to claim 23, wherein the ratio between the amount of ligand-binding analyte-specific receptor and the total amount of analyte-specific receptor is no more than about 1:20.

7

38. The test kit according to claim 26, wherein the ratio between said second amount of analyte-binding receptor substance immobilized to the solid phase, and the sum of said first and second amounts of analyte-binding receptor substance is no more than about 1:20.--

097282-101001
FOIbT 282/660

REMARKS

Claims 1-38 are pending in the present application. Entry of the above amendments is earnestly solicited. An early and favorable first action on the merits is earnestly solicited.

A marked-up version of the claims showing all changes is attached hereto.


Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact MaryAnne Armstrong, Ph.D. (Reg. 40,069) at the telephone number of the undersigned below.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By


Gerald M. Murphy, Jr., #28,977

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

GMM/MAA/csp:cqc
1614-0254P